Design and rationale of the URGENT dyspnea study: An international, multicenter, prospective study

Peter S. Pang, Miguel Tavares, Sean P. Collins, John G F Cleland, Judd Hollander, Markku Nieminen, Chadwick Miller, D. Mark Courtney, James D Kirk, Josep Masip, Alexander Parkhomenko, Cezar Macarie, W. Frank Peacock, Jindrich Spinar, Richard Nowak, Dimitar Raev, Alan B. Storrow, Vladimir Spisak, Ahmed Hamdy, Alexandre MebazaaMihai Gheorghiade

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Dyspnea is a key target in both clinical management and clinical trials of acute heart failure syndromes and its relief important to patients, clinicians, investigators, and regulatory approval agencies. Despite its importance, the impact of early therapy on dyspnea is not well known. The severity of dyspnea may also be influenced by the conditions under which it is measured (ie, sitting up or lying down). URGENT Dyspnea (Ularitide Global Evaluation in Acute Decompensated Heart Failure) is a prospective multicenter study designed to address these issues. Methods and Results: Consenting adult patients with dyspnea secondary to acute heart failure syndromes are eligible. Patients must be interviewed within one hour of first physician evaluation, typically in an emergency department or acute care setting, with dyspnea assessed by the patient using both a 5-point Likert scale and 10-point visual analog scale in the sitting (60°) and then supine (20°) position if symptomatically able. Improvement of dyspnea by change in Likert and visual analog scale scores at 6 h is the primary endpoint. Conclusions: Timing of dyspnea measurement and the conditions under which it is measured may influence dyspnea severity and this may have significant implications for future acute heart failure syndromes clinical trial design that target dyspnea.

Original languageEnglish (US)
Pages (from-to)299-303
Number of pages5
JournalAmerican Journal of Therapeutics
Volume15
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Dyspnea
Multicenter Studies
Prospective Studies
Heart Failure
Visual Analog Scale
Clinical Trials
Supine Position
Secondary Prevention
Hospital Emergency Service
Research Personnel
Physicians

Keywords

  • Acute heart failure syndromes
  • Dyspnea
  • Emergency department

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pang, P. S., Tavares, M., Collins, S. P., Cleland, J. G. F., Hollander, J., Nieminen, M., ... Gheorghiade, M. (2008). Design and rationale of the URGENT dyspnea study: An international, multicenter, prospective study. American Journal of Therapeutics, 15(4), 299-303. https://doi.org/10.1097/MJT.0b013e31816b436e

Design and rationale of the URGENT dyspnea study : An international, multicenter, prospective study. / Pang, Peter S.; Tavares, Miguel; Collins, Sean P.; Cleland, John G F; Hollander, Judd; Nieminen, Markku; Miller, Chadwick; Courtney, D. Mark; Kirk, James D; Masip, Josep; Parkhomenko, Alexander; Macarie, Cezar; Peacock, W. Frank; Spinar, Jindrich; Nowak, Richard; Raev, Dimitar; Storrow, Alan B.; Spisak, Vladimir; Hamdy, Ahmed; Mebazaa, Alexandre; Gheorghiade, Mihai.

In: American Journal of Therapeutics, Vol. 15, No. 4, 07.2008, p. 299-303.

Research output: Contribution to journalArticle

Pang, PS, Tavares, M, Collins, SP, Cleland, JGF, Hollander, J, Nieminen, M, Miller, C, Courtney, DM, Kirk, JD, Masip, J, Parkhomenko, A, Macarie, C, Peacock, WF, Spinar, J, Nowak, R, Raev, D, Storrow, AB, Spisak, V, Hamdy, A, Mebazaa, A & Gheorghiade, M 2008, 'Design and rationale of the URGENT dyspnea study: An international, multicenter, prospective study', American Journal of Therapeutics, vol. 15, no. 4, pp. 299-303. https://doi.org/10.1097/MJT.0b013e31816b436e
Pang, Peter S. ; Tavares, Miguel ; Collins, Sean P. ; Cleland, John G F ; Hollander, Judd ; Nieminen, Markku ; Miller, Chadwick ; Courtney, D. Mark ; Kirk, James D ; Masip, Josep ; Parkhomenko, Alexander ; Macarie, Cezar ; Peacock, W. Frank ; Spinar, Jindrich ; Nowak, Richard ; Raev, Dimitar ; Storrow, Alan B. ; Spisak, Vladimir ; Hamdy, Ahmed ; Mebazaa, Alexandre ; Gheorghiade, Mihai. / Design and rationale of the URGENT dyspnea study : An international, multicenter, prospective study. In: American Journal of Therapeutics. 2008 ; Vol. 15, No. 4. pp. 299-303.
@article{e7149b5b2e984b60a184d22cb2477c2e,
title = "Design and rationale of the URGENT dyspnea study: An international, multicenter, prospective study",
abstract = "Background: Dyspnea is a key target in both clinical management and clinical trials of acute heart failure syndromes and its relief important to patients, clinicians, investigators, and regulatory approval agencies. Despite its importance, the impact of early therapy on dyspnea is not well known. The severity of dyspnea may also be influenced by the conditions under which it is measured (ie, sitting up or lying down). URGENT Dyspnea (Ularitide Global Evaluation in Acute Decompensated Heart Failure) is a prospective multicenter study designed to address these issues. Methods and Results: Consenting adult patients with dyspnea secondary to acute heart failure syndromes are eligible. Patients must be interviewed within one hour of first physician evaluation, typically in an emergency department or acute care setting, with dyspnea assessed by the patient using both a 5-point Likert scale and 10-point visual analog scale in the sitting (60°) and then supine (20°) position if symptomatically able. Improvement of dyspnea by change in Likert and visual analog scale scores at 6 h is the primary endpoint. Conclusions: Timing of dyspnea measurement and the conditions under which it is measured may influence dyspnea severity and this may have significant implications for future acute heart failure syndromes clinical trial design that target dyspnea.",
keywords = "Acute heart failure syndromes, Dyspnea, Emergency department",
author = "Pang, {Peter S.} and Miguel Tavares and Collins, {Sean P.} and Cleland, {John G F} and Judd Hollander and Markku Nieminen and Chadwick Miller and Courtney, {D. Mark} and Kirk, {James D} and Josep Masip and Alexander Parkhomenko and Cezar Macarie and Peacock, {W. Frank} and Jindrich Spinar and Richard Nowak and Dimitar Raev and Storrow, {Alan B.} and Vladimir Spisak and Ahmed Hamdy and Alexandre Mebazaa and Mihai Gheorghiade",
year = "2008",
month = "7",
doi = "10.1097/MJT.0b013e31816b436e",
language = "English (US)",
volume = "15",
pages = "299--303",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Design and rationale of the URGENT dyspnea study

T2 - An international, multicenter, prospective study

AU - Pang, Peter S.

AU - Tavares, Miguel

AU - Collins, Sean P.

AU - Cleland, John G F

AU - Hollander, Judd

AU - Nieminen, Markku

AU - Miller, Chadwick

AU - Courtney, D. Mark

AU - Kirk, James D

AU - Masip, Josep

AU - Parkhomenko, Alexander

AU - Macarie, Cezar

AU - Peacock, W. Frank

AU - Spinar, Jindrich

AU - Nowak, Richard

AU - Raev, Dimitar

AU - Storrow, Alan B.

AU - Spisak, Vladimir

AU - Hamdy, Ahmed

AU - Mebazaa, Alexandre

AU - Gheorghiade, Mihai

PY - 2008/7

Y1 - 2008/7

N2 - Background: Dyspnea is a key target in both clinical management and clinical trials of acute heart failure syndromes and its relief important to patients, clinicians, investigators, and regulatory approval agencies. Despite its importance, the impact of early therapy on dyspnea is not well known. The severity of dyspnea may also be influenced by the conditions under which it is measured (ie, sitting up or lying down). URGENT Dyspnea (Ularitide Global Evaluation in Acute Decompensated Heart Failure) is a prospective multicenter study designed to address these issues. Methods and Results: Consenting adult patients with dyspnea secondary to acute heart failure syndromes are eligible. Patients must be interviewed within one hour of first physician evaluation, typically in an emergency department or acute care setting, with dyspnea assessed by the patient using both a 5-point Likert scale and 10-point visual analog scale in the sitting (60°) and then supine (20°) position if symptomatically able. Improvement of dyspnea by change in Likert and visual analog scale scores at 6 h is the primary endpoint. Conclusions: Timing of dyspnea measurement and the conditions under which it is measured may influence dyspnea severity and this may have significant implications for future acute heart failure syndromes clinical trial design that target dyspnea.

AB - Background: Dyspnea is a key target in both clinical management and clinical trials of acute heart failure syndromes and its relief important to patients, clinicians, investigators, and regulatory approval agencies. Despite its importance, the impact of early therapy on dyspnea is not well known. The severity of dyspnea may also be influenced by the conditions under which it is measured (ie, sitting up or lying down). URGENT Dyspnea (Ularitide Global Evaluation in Acute Decompensated Heart Failure) is a prospective multicenter study designed to address these issues. Methods and Results: Consenting adult patients with dyspnea secondary to acute heart failure syndromes are eligible. Patients must be interviewed within one hour of first physician evaluation, typically in an emergency department or acute care setting, with dyspnea assessed by the patient using both a 5-point Likert scale and 10-point visual analog scale in the sitting (60°) and then supine (20°) position if symptomatically able. Improvement of dyspnea by change in Likert and visual analog scale scores at 6 h is the primary endpoint. Conclusions: Timing of dyspnea measurement and the conditions under which it is measured may influence dyspnea severity and this may have significant implications for future acute heart failure syndromes clinical trial design that target dyspnea.

KW - Acute heart failure syndromes

KW - Dyspnea

KW - Emergency department

UR - http://www.scopus.com/inward/record.url?scp=51649097262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649097262&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e31816b436e

DO - 10.1097/MJT.0b013e31816b436e

M3 - Article

C2 - 18645329

AN - SCOPUS:51649097262

VL - 15

SP - 299

EP - 303

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 4

ER -